Daniel A. Erlanson

Daniel A Erlanson is a co-founder of Carmot Therapeutics. Prior to Carmot, Dr. Erlanson spent a decade developing technologies and leading medicinal chemistry efforts in oncology and in metabolic and inflammatory diseases at Sunesis Pharmaceuticals, which he joined at the company’s inception. Before Sunesis, he was an NIH postdoctoral fellow with James A Wells at Genentech. Dr. Erlanson earned his PhD in chemistry from Harvard University in the laboratory of Gregory L Verdine and his BA in chemistry from Carleton College. As well as co-editing two books on fragment-based drug discovery, Dr. Erlanson is an inventor or author on more than 40 patents and scientific publications. He is also editor of a blog devoted to fragment-based drug discovery, Practical Fragments.